Lyell to Host Investor Chats in November
Lyell Immunopharma's senior management will join investor conferences and fireside chats through November 18, 2026.
Updated on Nov. 2, 2026 in Corporate Finance
Lyell Immunopharma, a late-stage clinical company advancing next-generation CAR T-cell therapies, will participate in several investor events in November 2026. Participation includes a Goldman Sachs RxChange fireside chat, a Stifel 2026 Healthcare Conference fireside chat and 1x1 meetings, and 1x1 meetings at the Jefferies Global Healthcare Conference.
Why it matters
The scheduled sessions give investors and analysts direct access to Lyell's management ahead of the company's next phase of clinical and commercial development. Investor engagement at major healthcare conferences is a routine way for listed biotechnology companies to communicate their progress.
Lyell's LyFE Manufacturing Center is projected to produce more than 1,200 CAR T-cell doses per year, according to the company's announcement of its November 2026 investor schedule. The announcement does not address current production volumes or how that projection compares with capacity at other manufacturers.
The players
Lyell Immunopharma
Lyell Immunopharma is a late-stage clinical company developing next-generation CAR T-cell therapies and is listed on Nasdaq under the ticker LYEL.
The details
Lyell's senior management will take part in a Goldman Sachs RxChange Series fireside chat on Thursday, November 5, 2026, at 11:00 a.m. ET, focused on lymphoma CAR-T data. A Stifel fireside chat and 1x1 meetings follow on Tuesday, November 10, at 4:00 p.m. ET, with a live webcast and replay available in the Investors section of lyell.com.
Timeline
Thursday, November 5, 2026, at 11:00 a.m. ET: Goldman Sachs RxChange fireside chat
Tuesday, November 10, 2026, at 4:00 p.m. ET: Stifel 2026 Healthcare Conference fireside chat and 1x1 meetings
Wednesday, November 18, 2026: Jefferies Global Healthcare Conference 1x1 meetings
Market Dynamics
Lyell's investor schedule comes as CAR T-cell therapies, which gained their first FDA approvals with Kymriah and Yescarta, continue to move from clinical development toward commercial manufacturing. Companies in this space are increasingly judged on manufacturing scale, such as the LyFE facility's projected output of more than 1,200 doses per year.
Investors who follow LYEL can hear management's commentary directly at the scheduled fireside chats, and the Stifel session will be webcast live with a replay on lyell.com. The events are informational sessions, and the announcement does not indicate any change to the company's financial or clinical plans.
The takeaway
Following a company's scheduled investor events gives readers a direct line to management commentary on pipeline and manufacturing progress. Readers can check the Investors section of lyell.com for webcast links and replays.
What happens next
Lyell's senior management is scheduled to present at the Goldman Sachs, Stifel and Jefferies healthcare conferences between November 5 and November 18, 2026.
Further reading
Track company-level developments in the Corporate Finance section for context on how biotech firms approach investors.
More information
Find the event details and replay links on the Lyell Immunopharma investor relations website.
Source note: This article includes information reported by The Manila times.
